Latest news with #medicaldiagnostics
Arab News
2 days ago
- Business
- Arab News
Makkah Health Cluster brings AI-powered healthcare platform ‘iSelfie' to region
The Makkah Health Cluster has signed a cooperation agreement with Canadian company AIZTech, which specializes in AI-powered medical diagnostics, to deploy the iSelfie platform across its facilities, including King Abdullah Medical City and several major hospitals in Makkah. The signing ceremony was attended by Jean-Philippe Linteau, ambassador of Canada to Saudi Arabia; Dr. Mubarak Al-Mulhem, director general of healthcare at the Ministry of Investment; and Dr. Hatim Al-Omari, CEO of the Makkah Health Cluster, which oversees more than 10 hospitals in the city. Also present were Dr. Adel Tash, CEO of King Abdullah Medical City, and Tarek Sultan, vice chairman of Agility. The agreement was signed by Al-Omari and Mohamed Sheta, CEO of AIZTech. This marks the first agreement of its kind in the Middle East, allowing patients to benefit from instant health assessments using AI through a short facial video, with no additional hardware required. The iSelfie platform analyzes the video to extract key health metrics including blood pressure, heart rate, blood oxygen saturation, and respiratory rate. The platform will be integrated into the patient-facing screens within hospital facilities and will be used with the assistance of medical staff. Al-Omari said: 'We are proud to be the first in the Kingdom and the region to adopt this advanced technology, which reflects our ongoing commitment to harnessing the latest digital solutions to enhance diagnostic efficiency and accelerate patient care. This step marks a qualitative leap toward a more advanced and innovative healthcare system, aligned with the goals of Saudi Vision 2030.' Tash added: 'In line with the spirit of digital transformation and the ambitious Saudi Vision 2030, we are pleased to launch this innovative AI-powered technology in Makkah. This launch is backed by a pivotal study conducted across the Kingdom, where the technology showed promising results when compared with 1,021 cases diagnosed using traditional medical devices. We are committed to expanding access to these advanced tools to benefit the wider community in the region.' Sheta said: 'We are honored to collaborate with one of the Kingdom's leading public healthcare institutions. This agreement is a clear indicator of the growing trust in AI-powered healthcare solutions and reinforces our belief that remote, non-invasive early diagnostics will be a core part of healthcare's future.' Ambassador Linteau said: 'Digital health innovation is gaining momentum in Canada, and Saudi Arabia is a market that is open to early adoption of innovation in the health sector.' He also expressed hope that the platform will achieve remarkable success in the early detection of health conditions in patients. The iSelfie platform has proven its effectiveness through clinical trials conducted in Saudi Arabia, the US, Canada, and Brazil, including a national study supported by the Saudi Food and Drug Authority. Results showed that the platform provides accurate readings comparable to traditional medical devices, with the added benefits of rapid assessment, accessibility, and cost efficiency. This collaboration aligns with the goals of Saudi Vision 2030, which places innovation and digital transformation at the heart of healthcare development by improving the quality of life, promoting preventive care, and expanding access to modern medical services.
Yahoo
29-05-2025
- Business
- Yahoo
$46.5 Bn AI in Medical Diagnostics Market Opportunities and Strategies to 2034: Machine Learning and Computer Vision Set to Transform AI Diagnostics Landscape
Global AI in medical diagnostics market to surge from $1.92B in 2024 to $46.59B by 2034. Key growth drivers include aging population, rising healthcare expenditure, and tech innovations. Top players: Siemens Healthineers, Merative, Tempus Labs. Software to lead growth. Explore strategic insights. AI in Medical Diagnostics Market Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "AI in Medical Diagnostics Market Opportunities and Strategies to 2034" has been added to offering. The report on AI in medical diagnostics market highlights its historical and projected growth, analyzing regional trends and market dynamics from 2019 to 2034. The market, valued at $1.92 billion in 2024, is projected to soar to $46.59 billion by 2034, demonstrating a significant compound annual growth rate (CAGR) of 33.72% during the forecast period. Significant contributors to historical growth included rising demand for personalized medicine, increased adoption of cloud-based AI solutions, and the proliferation of chronic diseases. Despite this, challenges like ethical concerns and data protection issues posed barriers to expansion. Looking ahead, factors such as an aging global population, escalating healthcare expenditures, and supportive government measures are anticipated to propel market growth, although the high procurement costs could present hurdles. The market is dominated by key players, with Siemens Healthineers AG leading at an 11.10% market share in 2023. Other notable competitors include Merative L.P., Tempus Labs Inc., and Enlitic Inc. Geographically, North America remains the most significant market region, holding 41.12% of the 2024 market value, with Asia Pacific and the Middle East poised for the fastest growth in the coming years. By component, the software segment leads, representing 59.65% of the market in 2024 and projected to grow rapidly at a CAGR of 43.11%. Application-wise, computer-aided detection currently dominates the market, while computer-aided diagnosis is expected to expand fastest. Hospitals, as the primary end users, also represent the largest and fastest-growing segment by end-user category. In terms of technological segmentation, machine learning currently dominates, but computer vision is expected to see the quickest growth. The specialty segmentation identifies neurology as the largest segment, while radiology is set to experience rapid expansion. Emerging opportunities are identified in various segments, with the software segment anticipated to gain $5.73 billion by 2029. Similarly, hospitals, computer-aided detection, machine learning, and the neurology segment each present substantial revenue-generating potential. Trend-based strategies for market players emphasize optimizing operations through AI to enhance diagnostic accuracy and streamline workflows, ultimately boosting productivity and patient care. Advancements in radiology efficiency, innovations in vital sign monitoring, and personalized cancer therapies are highlighted. Engagement through strategic partnerships and sophisticated AI tools also play a pivotal role in shaping market dynamics. The report suggests specific strategies for AI medical diagnostics companies to capture market opportunities. These include optimizing AI for precision, enhancing radiology efficiency, and advancing healthcare workflows. Expanding into emerging markets, investing in innovative diagnostic tools, and maintaining competitive pricing are recommended approaches to thrive in the evolving landscape. Key Attributes: Report Attribute Details No. of Pages 315 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $1.92 Billion Forecasted Market Value (USD) by 2034 $46.59 Billion Compound Annual Growth Rate 37.6% Regions Covered Global Major Market Trends Utilizing AI to streamline medical operations and optimize care journeys across the healthcare system. Transforming healthcare efficiency with AI-driven radiology solutions for faster and more accurate results. Innovating healthcare workflows with AI to address clinician burnout and enhance productivity. Advancements in vital sign monitoring utilizing photoplethysmography and other sensor technologies. Enhancing personalized cancer therapies through AI-based biomarker identification. Launch of advanced diagnostics tools for detecting accurate and clinically reliable information. Integration of quantitative reporting in medical imaging for liver disease diagnosis. Increasing investments to revolutionize decision-making with personalized AI insights. Strategic partnerships and collaborations among major players. Market Segments Covered: Component: Software, Hardware, Services Application: Computer-Aided Detection, Diagnosis, Quantitative Analysis, Clinical Decision End User: Hospitals, Diagnostics Imaging Centers, Laboratories, Others Technology: NLP, Computer Vision, Machine Learning, Context-Aware Computing Specialty: Cardiology, Oncology, Pathology, Radiology, Chest and Lung, Neurology, Others Companies Featured Siemens Healthineers AG Merative L.P. Tempus Labs Inc. Enlitic Inc. GE Healthcare Technologies Inc. Microsoft Corporation Koninklijke Philips N.V. NVIDIA Corporation PathAI Inc. Aidoc Medical Ltd. Samsung Medison Co., Ltd. Wipro GE Healthcare Private Limited SK Telecom Healthians iHridAI InMed AI Olympus Corporation Anaut Inc. XtalPi Lunit Niramai Predible Healt Fujifilm Holdings Corporation Canon Medical Systems Hitachi Healthcare Vuno Inc. JLK Inspection 4DMedical HaloDoc AIHealth Ping An Good Doctor iFlytek HuiyiHuiying (HYHY) Ningbo Jansen NMR Technology Co., Ltd. YITU Technology Huawei Cloud Gleamer Guerbet Technologies Private Limited BioNTech SE Quantum Surgical Therapixel Merantix QUIBIM Nanobiosym Doctrin Icomera Sophia Genetics RetinAI Medical Eukarys Istituto Italiano di Tecnologia (IIT) Kheiron Medical Zaya AI Beeline Healbe Infermedica Syntellix AG Aireen CureMetrix Medo AI Caption Health DiA Imaging Analysis AI Precision Trillium Health Partners WELL Health Technologies Corp Stryker Corporation RadNet Beckman Coulter Diagnostics Exo Quest Diagnostics LabCorp Abbott Laboratories Thermo Fisher Scientific PathAI Diagnostics Bio-Rad Laboratories Becton Dickinson Agilent Technologies GenMark Diagnostics Butterfly Network Tempus AI Intel Corporation Micro Health LLC caption Health Inc. Dasha Coraline Soft Co Ltd. AI Medical Service Inc. International Business Machines Corp AliveCor, Inc. Digital Diagnostics Inc. Tamer Healthcare PureHealth Dell Technologies Astute Eyenuk, Inc. Dr CADx Envisionit Deep AI Ilara Health hearX Group Lancet Laboratories Dileny Technologies For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment AI in Medical Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
27-05-2025
- Business
- Associated Press
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ('Lucid' or the 'Company'), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. 'We are pleased that Lucid is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products,' said Dennis McGrath, Lucid's Chief Financial Officer. 'This important milestone is a testament to the significant progress Lucid has made in enhancing shareholder value over the past year. We are confident that it will increase our visibility and access to a broader range of institutional investors.' The broad-market Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization. The Russell 2000 Index is a subset of the broader Russell 3000 Index limited to small-cap companies. The indexes are reconstituted annually by re-ranking companies based on total market capitalization as of the reconstitution rank date, which was April 30, 2025, this year. Index membership remains in place for one year and results in automatic inclusion in the relevant growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to FTSE Russell, approximately $10.6 trillion in assets are benchmarked against the Russell U.S. Indexes. For more information on the Russell 2000® and Russell 3000® Indexes and the Russell indexes reconstitution, visit the 'Russell Reconstitution' section on the FTSE Russell website. About Lucid Diagnostics Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information about Lucid, please visit and for more information about its parent company PAVmed, please visit About FTSE Russell FTSE Russell is a leading global provider of benchmarking, analytics, and data solutions for investors, giving them a precise view of the market relevant to their investment process. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Forward-Looking Statements This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, 'Risk Factors,' in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, 'Risk Factors' in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. View original content to download multimedia: SOURCE Lucid Diagnostics
